DK0769967T3 - Konjugater der omfatter et antitumormiddel, og anvendelse heraf - Google Patents
Konjugater der omfatter et antitumormiddel, og anvendelse herafInfo
- Publication number
- DK0769967T3 DK0769967T3 DK95928905T DK95928905T DK0769967T3 DK 0769967 T3 DK0769967 T3 DK 0769967T3 DK 95928905 T DK95928905 T DK 95928905T DK 95928905 T DK95928905 T DK 95928905T DK 0769967 T3 DK0769967 T3 DK 0769967T3
- Authority
- DK
- Denmark
- Prior art keywords
- conjugates
- bond
- antitumor agent
- inhibits
- prodrugs
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Multicomponent Fibers (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9400752A BE1008581A3 (fr) | 1994-08-19 | 1994-08-19 | Prodrogues, composition pharmaceutique les comprenant et leur utilisation. |
BE9400751A BE1008580A3 (fr) | 1994-08-19 | 1994-08-19 | Prodrogues, composition pharmaceutiques les comprenant et leur utilisation. |
PCT/BE1995/000076 WO1996005863A1 (fr) | 1994-08-19 | 1995-08-21 | Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0769967T3 true DK0769967T3 (da) | 2008-03-31 |
Family
ID=25662908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95928905T DK0769967T3 (da) | 1994-08-19 | 1995-08-21 | Konjugater der omfatter et antitumormiddel, og anvendelse heraf |
Country Status (14)
Country | Link |
---|---|
US (5) | US5962216A (no) |
EP (2) | EP0769967B1 (no) |
JP (2) | JP4157600B2 (no) |
AT (1) | ATE380559T1 (no) |
AU (1) | AU694546C (no) |
CA (1) | CA2203622C (no) |
DE (1) | DE69535665T2 (no) |
DK (1) | DK0769967T3 (no) |
ES (1) | ES2297832T3 (no) |
NO (1) | NO324045B1 (no) |
NZ (1) | NZ291368A (no) |
PT (1) | PT769967E (no) |
SI (1) | SI0769967T1 (no) |
WO (1) | WO1996005863A1 (no) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6517824B1 (en) * | 1990-05-14 | 2003-02-11 | University Of Medicine & Denistry Of New Jersey | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
PT769967E (pt) * | 1994-08-19 | 2008-02-18 | Univ Catholique Louvain | Conjugados que compreendem um agente antitumoral e a sua utilização |
EP0923603A1 (en) * | 1996-07-16 | 1999-06-23 | Novo Nordisk A/S | Oligopeptide transporters |
US5998362A (en) * | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6127333A (en) * | 1997-07-10 | 2000-10-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
ES2342637T3 (es) * | 1998-12-11 | 2010-07-09 | Medarex, Inc. | Compuestos profarmacos y procedimiento para su preparacion. |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
EP2266607A3 (en) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
GB9924759D0 (en) | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
EP1228089A2 (en) | 1999-10-27 | 2002-08-07 | Merck & Co., Inc. | Salt form of a conjugate useful in the treatment of prostate cancer |
HUP0300590A2 (hu) | 2000-03-15 | 2003-07-28 | Bristol-Myers Squibb Pharma Company | Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk |
WO2001091798A2 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
US7115573B2 (en) * | 2000-06-14 | 2006-10-03 | Medarex, Inc. | Prodrug compounds with an isoleucine |
WO2001095945A2 (en) * | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Prodrug compounds cleavable by thimet oligopeptidase |
AU7552501A (en) * | 2000-06-14 | 2002-01-08 | Corixa Corp | Tripeptide prodrug compounds |
AU2001286727A1 (en) * | 2000-08-24 | 2002-03-04 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
NZ525552A (en) | 2000-11-09 | 2005-04-29 | Neopharm Inc | SN-38 lipid complexes with cardiolipin and methods of use for the treatment of cancers and multiple sclerosis |
CA2428971A1 (en) * | 2000-11-14 | 2003-05-01 | New River Pharmaceuticals Inc. | Conjugates of a therapeutic agent and a peptide carrier |
EP1355675A1 (en) * | 2001-01-30 | 2003-10-29 | Universite Catholique De Louvain | Anti-tumor compounds |
GB0105929D0 (en) * | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
WO2002096910A1 (en) * | 2001-05-31 | 2002-12-05 | Medarex, Inc. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
AU2002316539C1 (en) * | 2001-06-11 | 2008-10-30 | Medarex, Inc. | CD10-activated prodrug compounds |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
FR2858936A1 (fr) * | 2003-08-22 | 2005-02-25 | Diatos | Potentialisation de l'activation de prodrogues de haut poids moleculaire |
WO2005072061A2 (en) * | 2004-02-02 | 2005-08-11 | Biosight Ltd. | Conjugates for cancer therapy and diagnosis |
US20080132458A1 (en) * | 2004-03-10 | 2008-06-05 | Threshold Pharmaceuticals, Inc. | Hypoxia-Activated Anti-Cancer Agents |
JP4658507B2 (ja) * | 2004-03-31 | 2011-03-23 | 竹本容器株式会社 | 自開式キャップ機構 |
RU2402548C2 (ru) * | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
BRPI0510909A2 (pt) * | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
NZ556661A (en) * | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
US20070060534A1 (en) * | 2005-06-30 | 2007-03-15 | Threshold Pharmaceuticals, Inc. | Anthracycline analogs |
WO2007038658A2 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
CN101365679B (zh) | 2005-10-26 | 2012-11-14 | 梅达莱克斯公司 | 制备cc-1065类似物的方法和化合物 |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
CA2645347A1 (en) * | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
WO2008005942A2 (en) * | 2006-06-30 | 2008-01-10 | The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services. | Activatable probes and methods of use |
US7718044B2 (en) * | 2006-09-11 | 2010-05-18 | Seagate Technology Llc | Method for controlling shaft coating taper |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
CL2008000510A1 (es) | 2007-02-21 | 2008-08-22 | Medarex Inc | Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero. |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
FR2960153B1 (fr) * | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
WO2012109624A2 (en) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
EP2781919A1 (en) | 2013-03-19 | 2014-09-24 | Roche Diagniostics GmbH | Method / device for generating a corrected value of an analyte concentration in a sample of a body fluid |
WO2015127685A1 (en) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
WO2017093993A1 (en) | 2015-12-03 | 2017-06-08 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
IL259569B2 (en) | 2015-12-03 | 2024-03-01 | Biosight Ltd | Salts of cytarabine-amino acid conjugate |
CN106074556B (zh) * | 2016-06-14 | 2018-11-16 | 河南师范大学 | L型胞嘧啶丙氨酸在制备抗癌药物中的应用 |
AU2016429272A1 (en) | 2016-11-14 | 2019-05-02 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
WO2022043256A1 (en) | 2020-08-23 | 2022-03-03 | Cobiores Nv | Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents |
WO2022136586A1 (en) | 2020-12-22 | 2022-06-30 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE869485A (fr) * | 1978-08-03 | 1978-12-01 | Inst Internat De Pathologie Ce | Nouveaux derives de la doxorubicine, leur preparation et les compositions qui les contiennent |
US4296105A (en) * | 1978-08-03 | 1981-10-20 | Institut International De Pathologie Cellulaire Et Moleculaire | Derivatives of doxorubicine, their preparation and use |
US4277466A (en) * | 1978-08-29 | 1981-07-07 | Institut International De Pathologie Cellulaire Et Moleculaire | Complexes of DNA and esters derived from daunorubicine, their preparation and use |
US4719312A (en) * | 1978-10-02 | 1988-01-12 | Merck & Co., Inc. | Lysosometropic detergent therapeutic agents |
EP0009944B1 (en) * | 1978-10-02 | 1983-05-18 | Merck & Co. Inc. | Lysosomotropic fluorinated amine therapeutic agents and compositions containing them |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
BE882541A (fr) * | 1980-03-31 | 1980-07-16 | Inst Internat De Pathologie Ce | Nouvelles formes pharmaceutiques leur preparation et les compositions qui les contiennent |
DE3167679D1 (en) * | 1980-03-31 | 1985-01-24 | Inst Int Pathologie Cellulaire | Pharmaceutical forms, their preparation and compositions containing the same |
US4376765A (en) * | 1980-03-31 | 1983-03-15 | Institut International De Pathologie Cellulaire Et Moleculaire | Medicaments, their preparation and compositions containing same |
OA06421A (fr) * | 1980-06-10 | 1981-09-30 | Omnium Chimique Sa | Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides. |
US4639456A (en) * | 1980-06-10 | 1987-01-27 | Omnichem S.A. | Vinblastin-23-oyl amino acid derivatives |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
EP0124502B1 (fr) * | 1983-04-29 | 1991-06-12 | OMNICHEM Société anonyme | Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués |
FR2546163B1 (fr) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
EP0126344A2 (en) | 1983-05-20 | 1984-11-28 | Abbott Laboratories | Tripeptide esters of therapeutic agents |
JPS60233642A (ja) * | 1984-05-07 | 1985-11-20 | Fuji Photo Film Co Ltd | 写真画像の形成方法 |
FR2584293B1 (fr) * | 1985-07-04 | 1989-03-17 | Ire Celltarg Sa | Anticorps utiles comme agents de pilotage et conjugues les incorporant |
AU618029B2 (en) | 1987-11-02 | 1991-12-12 | Imperial Chemical Industries Plc | Polypeptide compounds |
FR2626882B1 (fr) * | 1988-02-08 | 1991-11-08 | Ire Celltarg Sa | Conjugues de derives de vinca comportant une chaine detergente en position c-3 |
DE3841764A1 (de) | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
US5220001A (en) * | 1989-10-25 | 1993-06-15 | Zaidan Hojim Biseibutsu Dong-A Pharm Co. | Anthracycline glycoside derivatives |
FI91777C (fi) * | 1990-04-02 | 1994-08-10 | Elomit Oy | Menetelmä plasmiiniaktiivisuuden määrittämiseksi |
US5618790A (en) * | 1990-10-05 | 1997-04-08 | Queen's University At Kingston | Protease mediated drug delivery system |
KR100334697B1 (ko) | 1991-08-05 | 2002-04-27 | 리차아드제이마세이 | 표적화된 촉매 단백질에 의해 활성화되는 선구 약제 |
WO1994007518A1 (en) | 1992-09-25 | 1994-04-14 | Abbott Laboratories | Anaphylatoxin receptor ligands containing lipophilic residues |
JPH08505854A (ja) | 1993-01-14 | 1996-06-25 | マガイニン ファーマシューティカルズ,インク. | 修飾された末端を有するアミノ酸及びペプチド |
US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
US6143864A (en) | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
PT769967E (pt) * | 1994-08-19 | 2008-02-18 | Univ Catholique Louvain | Conjugados que compreendem um agente antitumoral e a sua utilização |
US5659061A (en) * | 1995-04-20 | 1997-08-19 | Drug Innovation & Design, Inc. | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
MXPA01011502A (es) | 1999-05-14 | 2003-08-20 | Boehringer Ingelheim Pharma | Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas. |
US6552166B1 (en) | 1999-10-19 | 2003-04-22 | Merck & Co., Inc. | Process for the preparation of conjugates useful in the treatment of prostate cancer |
EP1228089A2 (en) | 1999-10-27 | 2002-08-07 | Merck & Co., Inc. | Salt form of a conjugate useful in the treatment of prostate cancer |
-
1995
- 1995-08-21 PT PT95928905T patent/PT769967E/pt unknown
- 1995-08-21 WO PCT/BE1995/000076 patent/WO1996005863A1/fr active IP Right Grant
- 1995-08-21 EP EP95928905A patent/EP0769967B1/fr not_active Expired - Lifetime
- 1995-08-21 DK DK95928905T patent/DK0769967T3/da active
- 1995-08-21 AU AU32486/95A patent/AU694546C/en not_active Expired
- 1995-08-21 ES ES95928905T patent/ES2297832T3/es not_active Expired - Lifetime
- 1995-08-21 NZ NZ291368A patent/NZ291368A/en not_active IP Right Cessation
- 1995-08-21 US US08/793,910 patent/US5962216A/en not_active Expired - Lifetime
- 1995-08-21 SI SI9530732T patent/SI0769967T1/sl unknown
- 1995-08-21 CA CA2203622A patent/CA2203622C/en not_active Expired - Lifetime
- 1995-08-21 AT AT95928905T patent/ATE380559T1/de active
- 1995-08-21 EP EP07119790A patent/EP1880737A1/fr not_active Withdrawn
- 1995-08-21 JP JP50766296A patent/JP4157600B2/ja not_active Expired - Lifetime
- 1995-08-21 DE DE69535665T patent/DE69535665T2/de not_active Expired - Lifetime
-
1997
- 1997-02-18 NO NO19970748A patent/NO324045B1/no not_active IP Right Cessation
-
1999
- 1999-04-23 US US09/298,330 patent/US6342480B1/en not_active Expired - Lifetime
-
2001
- 2001-11-09 US US10/012,576 patent/US7037898B2/en not_active Expired - Fee Related
-
2006
- 2006-03-08 US US11/370,290 patent/US7390629B2/en not_active Expired - Fee Related
-
2007
- 2007-11-21 JP JP2007301893A patent/JP2008069175A/ja active Pending
-
2008
- 2008-06-10 US US12/157,363 patent/US7951772B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0769967A1 (fr) | 1997-05-02 |
US6342480B1 (en) | 2002-01-29 |
NO324045B1 (no) | 2007-08-06 |
NO970748D0 (no) | 1997-02-18 |
WO1996005863A1 (fr) | 1996-02-29 |
US7037898B2 (en) | 2006-05-02 |
EP0769967B1 (fr) | 2007-12-12 |
DE69535665D1 (de) | 2008-01-24 |
US7951772B2 (en) | 2011-05-31 |
AU3248695A (en) | 1996-03-14 |
JPH10508291A (ja) | 1998-08-18 |
ES2297832T3 (es) | 2008-05-01 |
US5962216A (en) | 1999-10-05 |
US20020160943A1 (en) | 2002-10-31 |
AU694546B2 (en) | 1998-07-23 |
DE69535665T2 (de) | 2009-04-02 |
US20060148682A1 (en) | 2006-07-06 |
NZ291368A (en) | 1999-04-29 |
US20090137494A1 (en) | 2009-05-28 |
CA2203622C (en) | 2011-11-01 |
JP2008069175A (ja) | 2008-03-27 |
PT769967E (pt) | 2008-02-18 |
CA2203622A1 (en) | 1996-02-29 |
US7390629B2 (en) | 2008-06-24 |
JP4157600B2 (ja) | 2008-10-01 |
MX9701283A (es) | 1997-09-30 |
NO970748L (no) | 1997-04-10 |
SI0769967T1 (sl) | 2008-06-30 |
EP1880737A1 (fr) | 2008-01-23 |
AU694546C (en) | 2001-09-06 |
ATE380559T1 (de) | 2007-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0769967T3 (da) | Konjugater der omfatter et antitumormiddel, og anvendelse heraf | |
DE69941429D1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
BR0215397A (pt) | Pensos cirúrgicos revestidos | |
SE8000469L (sv) | Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning | |
DE69737684D1 (de) | Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika | |
DE69822805D1 (de) | Verbesserte arzneiverabreichung an schleimhautoberflächen | |
ES2194180T3 (es) | Nuevas fenantridinas. | |
DE69735901D1 (de) | Verbesseringen an oder in verbindung mit diagnostischen/therapeutischen mitteln | |
DE69826684D1 (de) | Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen | |
TR200103493T2 (tr) | Metaloproteaz önleyicileri | |
MX9603570A (es) | Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. | |
ATE416676T1 (de) | Vaskuläre okklusionsvorrichtung | |
NO996443L (no) | Stedsrettet kjemoterapi av metastaser | |
AU8439998A (en) | Compounds | |
FI891718A0 (fi) | Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer. | |
DE3889236D1 (de) | Photopolymerisierbare Zusammensetzung. | |
SE9703650D0 (sv) | Koncentrat för dialyslösning och användning | |
ATE248820T1 (de) | Haftvermittler | |
DE60003289D1 (de) | Kombinationstherapie für lymphoproliferative krankheiten | |
SE8501882L (sv) | Pyridinderivat och framstellning derav | |
ES8704962A1 (es) | Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida. | |
AR245340A1 (es) | Composicion herbicida selectiva de accion sinergica para el cultivo de cereales y procedimiento para su obtencion. | |
SE9902742D0 (sv) | New pharmaceutical formultion | |
ATE222103T1 (de) | Inklusionskomplexe in waessriger loesung | |
ATE366587T1 (de) | Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung |